Adagene Inc. (ADAG) AI Stock Analysis

Adagene Inc. is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, focused on the research, development, and production of monoclonal antibody drugs for cancer treatment. Founded in 2011, the company employs 128 people and utilizes proprietary research platforms and strategic collaborations to advance its oncology pipeline. Its product candidates include ADG106, an agonistic anti-CD137 monoclonal antibody in Phase 1b/2 trials for advanced solid tumors and non-Hodgkin's lymphoma. It is also testing anti-CTLA-4 candidates ADG126 and ADG116 in Phase 1 trials, anti-PD-L1 candidate ADG104 in Phase 2 trials, and anti-CSF-1R candidate ADG125 in Phase 1 development.

Adagene's revenue has fluctuated significantly, posting $10.2M in FY2021, $9.3M in FY2022, and $18.1M in FY2023, before plunging to $103,204 in FY2024. In FY2025, revenue rebounded by 7332.8% to $7.7M, supported by a 100.0% gross margin. Operating margins have remained deeply negative, improving from -711.2% in FY2021 to -279.5% in FY2025 as research and development expenses declined from $68.1M to $22.0M. Net income improved from a loss of -$73.2M in FY2021 to -$17.6M in FY2025. Over the trailing twelve months ended June 30, 2026, revenue stood at $9.3M with quarterly revenue growth of 7332.8% year-over-year, alongside a profit margin of -220.8%.

As of June 30, 2026, Adagene held $127.9M in cash and short-term investments against $6.1M in total debt, resulting in a net cash balance of $121.8M. Liquidity is supported by a current ratio of 5.02 and a low debt-to-equity ratio of 0.06 on shareholders' equity of $106.0M. Free cash flow for FY2025 was -$15.7M, reflecting a reduced cash burn compared to -$45.9M in FY2021. Capital expenditures for FY2025 totaled $17,053, and the company's share count decreased 17.0% over five years.

Adagene trades at an enterprise value of $76.3M and a market capitalization of $138.3M. Its price-to-sales ratio stands at 14.9x, compared to 4.1x for the median of its US-listed Healthcare peers. The company's EV/EBITDA multiple is 1.1x, below the peer group median of 12.0x, while price-to-book is 2.2x. Over the past year, ADAG gained 15.7%, trailing the S&P 500 (SPY) return of 16.8%. Over a five-year span, the stock fell 82.4%, compared to an 83.0% gain for the S&P 500. Shares closed at $2.06 on October 16, 2026, which is 39.2% below their 200-day average.

Wall Street coverage consists of 6 Strong Buy ratings, with no Buy, Hold, Sell, or Strong Sell ratings. The mean price target of $9.91 sits 381.0% above the last close of $2.06. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $2.0M and EPS of -$0.51. For the following fiscal year, 5 analysts project revenue to expand 129.6% to $4.5M with an estimated EPS of -$0.59. The company has beaten EPS expectations in 3 of the last 4 quarters.

This page is an AI-written research summary of Adagene Inc. (ADAG). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ADAG income statement, ADAG balance sheet, ADAG key metrics, ADAG analyst forecast, ADAG chart. See the ADAG stock overview for the latest quote and news.